Pharma Site Readiness: From Project Handover to Stable Operations

A project can complete its deliverables without the receiving organization being ready to operate them. Site readiness closes that gap by connecting project completion to operational ownership, controlled execution, and sustained performance.

Define Handover as an Operating Transition

Handover should answer more than “Was the asset or system delivered?” It should confirm who owns it, how it will be operated and supported, which procedures and data are required, what training is complete, and how open items will be controlled.

Establish Readiness Domains

Site readiness commonly spans organization and staffing, procedures, training, systems, master data, materials, maintenance, support services, vendors, business continuity, performance management, and governance.

Each domain needs an owner and acceptance criteria connected to the site startup sequence.

Control Open Items

Not every item must be closed before startup, but every exception must be understood. Record risk, impact, interim control, accountable owner, approval, and closure date. Do not allow punch-list volume to replace risk-based judgment.

Test Operating Scenarios

Use representative scenarios to confirm that the site can execute across functions. Include normal operations, common exceptions, escalation, system downtime, material constraints, and support response.

Plan Stabilization

Define the initial operating cadence, issue triage, performance indicators, staffing support, vendor coverage, and criteria for transferring from startup governance to steady-state management.

Business Takeaway

Site readiness is successful when project outputs become reliable operational capability. That requires planned ownership, tested handoffs, controlled exceptions, and a deliberate stabilization period.

CTA: RCG helps teams integrate handover and operational readiness into one execution model. Discuss your site readiness plan: https://readinessconsultinggroup.com/get-started.

Previous
Previous

Governance and Decision Cadence for Complex Pharma Programs

Next
Next

Cross-Functional Execution in GxP Programs